FGF2 and B-cell chronic lymphocytic leukemia: Kay et al. [19] indicated that B-CLL cells expresssed pro- and antiangiogenic molecules, and Shanafelt and Kay [20] observed, that the ratio of proangiogenic FGF-2 and antiangiogenic thrombospondin-1 (TSP-1) correlated with the time to treatment.